Accelerate biotechnology

$6.5M grant to take next step towards polio-free world

Leiden, the Netherlands, Sep 16, 2019 – Today, Batavia Biosciences announces it received a grant of $6.5 million from the Bill & Melinda Gates Foundation to develop a manufacturing process for a novel oral vaccine against polio virus type 2 strain (nOPV2) to help protect children worldwide from future polio outbreaks.

In a collaboration with PATH and Bio Farma, one of the world’s leading OPV manufacturers, Batavia Biosciences is currently producing attenuated and safe novel oral polio vaccine (nOPV) candidates in its Good Manufacturing Practices (GMP) facility. The nOPV2 vaccine to be developed under the grant from the Bill & Melinda Gates Foundation is the first nOPV vaccine to go through clinical development, to be followed by vaccines for nOPV1 and nOPV3.

Chris Yallop, CSO of Batavia Biosciences, explains: “The nOPV2 vaccine, provided by our partner Bio Farma, is currently the most advanced in clinical development and most in demand. The successful development of a low-cost manufacturing process for the novel PV2 strain will allow us to next apply our developed process to the novel PV1 and PV3 strains.”

The manufacturing process for the nOPV2 vaccine is based on the same highly intensified, low-cost vaccine manufacturing platform that Batavia Biosciences developed together with Univercells for the inactivated Sabin polio vaccine (sIPV). The platform combines Univercells NevoLine™ manufacturing technology with Batavia Biosciences’ Highly Intensified Process (HIP-Vax) technology for viral vaccines.

Menzo Havenga, CEO of Batavia Biosciences, comments: “We are very excited to work with these eminent partners and take the next step towards a polio-free world. Only by working closely together will we be able to protect every last child from all forms of poliovirus.”